Please login to the form below

Not currently logged in
Email:
Password:

Ali Alloueche to lead business strategy at Austrian biopharma Affiris

Former GSK and Novartis man Ali Alloueche will take over new chief business officer position established to deal with Affiris' growing pipeline of vaccines

Affiris has appointed Ali Alloueche, formerly of both GlaxoSmithKline (GSK) and Novartis, to fill its newly-created position of chief business officer.

The Austrian biopharmaceutical company said the role's creation was driven by its expanding pipeline of potential new vaccines for neurological disorders such as Alzheimer's disease.

Alloueche has several years of experience working in vaccine development for major pharmaceutical companies.

His most recent role was as head of external R&D at GlaxoSmithKline Biologicals in Belgium. While working for GSK he identified in-licensing opportunities for Alzheimer´s disease vaccine candidates produced by Affiris that resulted in a €430m deal for the Austrian company.

He has also worked as research director at Novartis Vaccines and Diagnostics in Italy and was head of translational medicine and scientific affairs at the company.

“The experience he has gained in senior positions at two top ten pharmaceutical companies is a valuable addition to Affiris´s in-house expertise,” said Walter Schmidt, Affiris' co-founder and CEO.

The company, which focuses its research on Alzheimer's and Parkinson's disease currently has four vaccine candidates in its pipeline. In his new role Alloueche will oversee Affiris' business activities, strategic alliances and partnerships.

Alloueche said: "Affiris is one of the most dynamic biopharmaceutical companies in Europe. The company´s focus on clinical programmes and its robust financial position offer great business opportunities."

6th December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics